Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 330
- Registration Number
- NCT00485979
- Locations
- 🇺🇾
Sanofi-Aventis Administrative Office, Montevideo, Uruguay
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT00475670
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 105
- Registration Number
- NCT00464646
- Locations
- 🇺🇸
CCOP, Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University Hospital and Medical Center - SUNY, Stony Brook, New York, United States
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00458237
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT00448279
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 127
- Registration Number
- NCT00446030
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer
- Conditions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- National Cancer Institute, Naples
- Registration Number
- NCT00434031
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 39
- Registration Number
- NCT00431704
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Danish Breast Cancer Cooperative Group
- Target Recruit Count
- 300
- Registration Number
- NCT00430001
- Locations
- 🇩🇰
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2011-07-21
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 75
- Registration Number
- NCT00429247
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.